Blood-test screening and prevention plan for heart failure in adults with type 2 diabetes
Tests a blood-test-guided heart failure screening and prevention plan in type 2 diabetes.
Plain-language title generated from the registry record
Registry title: NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
Key facts
- Where
- Dallas, United StatesSee the 3 sites
Where in United States
- Baylor Scott and White Health SystemDallas, United StatesTaking people
- Parkland Health & Hospital System (PHHS)Dallas, United StatesTaking people
- University of Texas Southwestern Medical CenterDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT06593327
- Record updated
- 29 September 2026
- Original description
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.Read full original descriptionShow less
Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Inclusion: Primary Care Provider that sees diabetes patients in clinic.
Exclusion: Provider does not see patients with Diabetes.